Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

European regulators are to review Sandoz's biosimilars of the inflammatory diseases medicines, Humira and Remicade, as competition intensifies to take market share from big-selling monoclonal anti ...

It is going up against several mature product franchises, including Amgen's Enbrel (etanercept), Abbott's Humira and Remicade, marketed in the US by J&J and in Europe by Merck of Whitehouse ...